Print Page  |  Close Window

2017 Press Releases

DateTitle and SummaryView
June 19, 2017VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor TypesData to be Presented at 2017 BIO International Convention in San Diego, CA TEL AVIV, Israel, June 19, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) provided an update on the long term status and survival of patients from three completed Phase 2 trials, which investigated the company’s lead candidate, VB-111, respectively in recurrent g
June 15, 2017VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating OfficerIndustry leader with extensive oncology experience joins company as VB-111 advances toward registration TEL AVIV, Israel, June 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr. Epperly is an oncology expert with industry background in drug
June 14, 2017VBL Therapeutics to Present at Upcoming June ConferencesUpdate on Long term Survival of VB-111 Treated Patients to be Presented at BIO on June 20 TEL AVIV, Israel, June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats, CEO,  will provide a corporate overview at the 2017 BIO International Convention in San Diego and participate in a panel on novel approache
June 08, 2017VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation AuthorityTEL AVIV, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million) by the Israel Innovation Authority.  The grant will support clinical trials and development activities for calendar year 2017.  The Israel Innovation A
June 05, 2017New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBMTEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene obadenovec) induced durable tumor regression and attenuation of tumor growth in patients with recurrent glioblastoma (rGBM). Data from the company’s prior Phase 2 st
May 15, 2017VBL Therapeutics Announces First Quarter 2017 Financial ResultsTEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced financial results for the first quarter ended March 31, 2017, as well as a corporate update. “We continue to exe
May 11, 2017VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT MeetingTEL AVIV, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the anti-tumor activity of a PD-L1 blocker in lung cancer and melanoma models. The data will be presented tomorrow, May 12, in a poster session at the 20th A
May 03, 2017VBL Therapeutics to Report First Quarter 2017 Results on May 15TEL AVIV, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2017 at 8:30am Eastern Time to
April 25, 2017VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 ConferencesTEL AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that new data on VB-111 will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, to be held June 2-6 in Chicago, Illinois, as well as in the 20th Annual Meeting of the American Society of Gene & Cell Therap
April 20, 2017VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBMTEL AVIV, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the Independent Data Safety Monitoring Committee (DSMC) met to conduct its second safety review of the Phase 3 GLOBE Study investigating ofranergene obadenovec (VB-111) in recurrent glioblastoma (rGBM).  The DSMC is an independent multidiscip
April 04, 2017VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology TargetTEL AVIV, Israel, April 04, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study, entitled "MOSPD2, a Newly Characterized Protein, Promotes Breast Cancer Metastasis" by Mendel et al., will be presented today at the American Association of
April 03, 2017VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASHPhase 2 Study of VB-201 Shows Reduction in Liver Enzymes Data Presented Today at H.C. Wainwright Annual NASH Investor Conference TEL AVIV, Israel, April 03, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced today that in a post-hoc, hypothesis-driven analysis of data from completed Phase 2 studies,  VB-201 appears to reduce c
March 28, 2017VBL Therapeutics to Present at the H.C. Wainwright NASH Investor ConferenceTEL AVIV, Israel, March 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the H.C. Wainwright 1st Annual NASH Investor Conference, being held
March 27, 2017VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial ResultsInterim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018 Phase 3 Study of VB-111 in Ovarian Cancer Currently Expected to Begin Enrollment in the Second Half of 2017 TEL AVIV, Israel, March 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology compa
March 23, 2017VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to OncologyTEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that it will be hosting a Key Opinion Leader breakfast on new targets and immunotherapeutic approaches to oncology, on April 6, 2017 in New York City. The meeting will feature a presentation by key opinion leader Ramy Ibrahim, MD (Parker Institu
March 15, 2017VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceTEL AVIV, Israel, March 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, being held March
March 07, 2017VBL Therapeutics to Present at the 29th Annual ROTH ConferenceTEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017 at th
March 02, 2017VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, March 27, 2017 at 8:30am Eastern Time
February 21, 2017VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid CancerTEL AVIV, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today full results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer. The data will be presented today by Dror Harats, M.D., CEO of VBL Therapeutics, at the Federation of the Is
February 06, 2017VBL Therapeutics to Present at the 2017 BIO CEO & Investor ConferenceTEL AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the BIO CEO & Investor Conference, being held on February 13-14,
January 31, 2017VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology TargetTEL AVIV, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper, entitled, "Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration" by Mendel et al., is published online
January 09, 2017VBL Therapeutics Provides Year End 2016 Corporate UpdateTEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017. Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch a Phase 3 trial of VB-111 in Ovarian Cancer during the second half of 2017. Interim analysis in the GL
January 06, 2017VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE StudyCompany Reiterates Guidance for GLOBE Interim Analysis to Occur in Mid-2017 and Final Analysis in Early 2018 TEL AVIV, Israel, Jan. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead candidate ofranergene obadenovec (VB-111)